Watching Teladoc Health, Inc.? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planFunding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Back to SEC FilingsExecutive ChangeItem 5.02 · 8-KLOW RiskPositive
Teladoc Health, Inc.
teladoc.comFiled: Aug 3, 2026CIK: 0001477449Healthcare
AI Executive Summary
AI-powered analysis of 8-K filing content
Teladoc Health appointed Mark V. Anquillare as a new independent director effective August 3, 2026, expanding the board to ten members. Anquillare will serve on both the audit and compensation committees and qualifies as an audit committee financial expert, strengthening the company's governance structure.
Key Takeaways
Board size increased from nine to ten members with the appointment of Mark V. Anquillare
Anquillare designated as independent director under NYSE standards and audit committee financial expert under SEC regulations
2 more takeaways
Filing Overview
Form Type8-K
Filing DateAug 3, 2026
Item5.02
CategoryExecutive Change
CIK0001477449
Accession #tdoc-20260803
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board change
What This Means
A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.